Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ACOG updates pap test guidelines

This article was originally published in The Gray Sheet

Executive Summary

Routine cervical cytology cancer screening should be delayed until age 21, according to guidelines released Nov. 20 by the American College of Obstetricians and Gynecologists. ACOG previously recommended that screening begin three years after first sexual intercourse or by age 21. The updated guidelines also call for women 21-30 to be screened less often - every two years instead of annually, using either the standard Pap test or liquid-based cytology. In a Practice Bulletin to be published in the December issue of Obstetrics & Gynecology, AGOG explains that "the recommendation to start screening at 21 years regardless of the age of onset of sexual intercourse is based in part on the very low incidence of cancer in younger women," as well as the potential for adverse effects associated with follow-up of young women with abnormal cytology screening results. Screening can jump to every three years in women 30 and older who have had three consecutive cervical cytology test results that are negative for intraepithelial lesions and malignancy, ACOG notes. Women with defined risk factors may benefit from more frequent screening, the guidelines state

You may also be interested in...

HPV Testing Evidence Examined In Cervical Cancer Screening Guidelines

The U.S. Preventive Services Task Force finds the evidence inconclusive for employing human papillomavirus testing as part of cervical cancer screening for women over 30, and it explicitly recommends against HPV testing in younger women.

QUOTED. 6 April 2020. Bethany Hills.

Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.

Health And Wellness Trademark Review 31 March, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts